A fall in serum levels of H2S has been associated with increased mortality in hospitalized COVID-19 patients, whereas these serum levels correlate inversely with the inflammation markers interleukin-6 (IL-6) and C-reactive protein, known markers for an adverse outcome; hence, nutraceuticals that support H2S production may have a protective anti-inflammatory impact in this syndrome [255]. This evidence concerns the gene CRP and COVID-19.